Navigation Links
New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
Date:1/10/2011

BOSTON, Jan. 10, 2011 /PRNewswire/ -- Entrega, Inc., a new company developing oral drug delivery technologies, today announced its formation by Enlight Biosciences, a Boston-based company established in partnership with a group of leading global pharmaceutical companies. As part of its initial development program, Entrega will use its unique spatially-directed proprietary drug delivery platform to create orally bioavailable formulations of several of the biologic drugs of Enlight's pharmaceutical industry partners, for which Entrega will receive undisclosed payments including upfront and research milestone payments.  Entrega will remain independent and retain all rights to the platform technology.

(Logo: http://photos.prnewswire.com/prnh/20110110/NE26979LOGO)

"Entrega's technology could have a major impact on medicine by enabling the oral delivery of drugs that would typically require injection," said Dr. Robert Langer, David H. Koch Institute Professor at MIT, Entrega SAB Chair. "The relationship with pharma will support Entrega's unique technology and strengthen the platform significantly."  

Biologic drugs (biologics), such as insulin and antibodies, represent over $120 Billion in annual revenues and address major medical needs in areas such as cancer and inflammatory disease.  However, most biologics need to be delivered by injection, which leads to challenges in compliance and effectiveness. The ability to deliver biologics orally would address a significant unmet need for patients around the world. Entrega's proprietary drug delivery technology offers an innovative approach to deliver a wide variety of peptides and proteins via oral administration.

Entrega, Inc. was formed by Enlight Biosciences, a unique entrepreneurial collaboration to discover and develop platform technologies that will have a transformational impact on drug discovery and devel
'/>"/>

SOURCE Entrega, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
3. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
4. Savient Submits Biologics License Application (BLA) for pegloticase
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
7. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
8. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
9. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
10. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The fully automated supercritical fluidic ... sequentially analyze up to 48 samples utilizing automatic ... of targets by mass spectrometry. , The ... measurement requirements of a wide range of applications, ... and search for disease biomarkers, additives in forming ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... Matrox Graphics Inc., the leading,manufacturer of specialized ... Matrox Xenia(TM) Series display controller boards with its,ME/CCL ... first native PCI Express single-slot board with,all-digital, triple-monitor ... configuration. Xenia Series supports resolutions from <1MP to,8MP ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today ... presentation of favorable data,generated by scientists at Amgen, ... scheduled presentation by Dr. Paul Pevsner of the,NYU ... in identifying potential protein,biomarkers in colon cancer samples, ...
... 8 Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical ... President and Chief Financial Officer,is scheduled to present ... in New York City on Monday, October 13, ... webcast of the presentation will be available at, ...
Cached Biology Technology:Totoku Europe Chooses Matrox Xenia(TM) Series to Drive Medical Monitors 2Pressure BioSciences, Inc. Provides Corporate Update 2Pressure BioSciences, Inc. Provides Corporate Update 3Pressure BioSciences, Inc. Provides Corporate Update 4Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... underway in three UK prisons to investigate the link ... the study will look at which nutrients are most ... volunteers from three young offenders institutions housing male prisoners ... top of their normal choice of food to ensure ...
... study sheds light on the relationship between women who ... increased risk of SIDS to their babies. Researchers ... why an infants ability to respond to oxygen deprivation ... to nicotine in the womb, even light to moderate ...
... Lack of oxygen isnt the only way that carbon ... Island Hospital. According to the findings of ... Academic Emergency Medicine, CO also causes direct damage to ... deprivation, which reduces the hearts pumping capacity and permanently ...
Cached Biology News:Prison study to investigate link between diet and behavior 2New research explains link between smoking and SIDS 2Carbon monoxide may cause long-lasting heart damage 2
... IgG FITC is used as the ... on tissues or culture cells where ... rabbits. It is highly recommended that ... the primary antibody, be included in ...
... 75 x 25 mm; approximately 1 mm thick, ... paraffin-embedded sections, sandblasted frosted ... markings will not rub off or wash ... precleaned, store at room ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Donor feline serum and plasma...
Biology Products: